Trevi Therapeutics (TRVI) Other Non-Current Liabilities (2018 - 2022)
Trevi Therapeutics (TRVI) posted quarterly Other Non-Current Liabilities of $3000.0 for Q4 2022, down 97.37% year-over-year from $114000.0 in Q4 2021, and down 80.0% quarter-over-quarter from $15000.0 in Q3 2022.
Trevi Therapeutics (TRVI) Other Non-Current Liabilities (2018 - 2022) Analysis & Trends
Trevi Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $3000.0 for Q4 2022.
- In Q4 2022, Other Non-Current Liabilities fell 97.37% year-over-year to $3000.0; the TTM figure through Dec 2022 stood at $3000.0 (down 97.37% YoY), while the FY2022 annual figure was $3000.0, down 97.37% from the prior year.
- Other Non-Current Liabilities for Q4 2022 stood at $3000.0, down from $15000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.1 million in Q4 2018, with the low at $3000.0 in Q4 2022.
- The 4-year median for Other Non-Current Liabilities is $125000.0 (2022), against an average of $197636.4.
- Peak annual rise in Other Non-Current Liabilities reached 2.94% in 2022, while the deepest fall reached 97.37% in 2022.
- Trevi Therapeutics' Other Non-Current Liabilities stood at $1.1 million in 2018, then sank by 82.12% to $196000.0 in 2020, then sank by 41.84% to $114000.0 in 2021, then plunged by 97.37% to $3000.0 in 2022.
- Business Quant data shows TRVI's Other Non-Current Liabilities at $3000.0 in Q4 2022, $15000.0 in Q3 2022, and $35000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 15,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 125,000.00 |
| Dec 31, 2021 | 114,000.00 |
| Sep 30, 2021 | 167,000.00 |
| Jun 30, 2021 | 34,000.00 |
| Mar 31, 2021 | 202,000.00 |
| Dec 31, 2020 | 196,000.00 |
| Sep 30, 2020 | 187,000.00 |
| Dec 31, 2018 | 1.10 Mn |